Home » Topics » BioWorld Science

BioWorld Science
RSS

Beijing Scitech-Mq Pharmaceuticals describes RET and VEGFR2 inhibitors

Sep. 4, 2019

Jiangsu Aosaikang Pharmaceutical identifies H+/K+ ATPase inhibitors

Sep. 4, 2019

Phase II trial of AR-105 for ventilator-associated pneumonia does not meet primary endpoint

Sep. 4, 2019

Medshine Discovery divulges kynurenine production inhibitors

Sep. 4, 2019

Turning Point Therapeutics reports new data on repotrectinib and TPX-0046

Sep. 4, 2019

Positive preclinical data presented for Cocrystal Pharma's CC-42344

Sep. 4, 2019

Pfizer synthesizes new KRAS inhibitors

Sep. 4, 2019

Phase III AMPLIFY study of phosphate absorption inhibitor tenapanor meets primary endpoint

Sep. 4, 2019

Discovery of a first-in-class dual adenosine A2A/A2B receptor antagonist

Sep. 4, 2019

Machine learning from adversity speeds compound development

Sep. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
Research grants support early clinical trials of ALS treatments
BioWorld Science
The ALS Association has announced the recipients of its 2025 Hoffman ALS Clinical Trial Awards. These research grants, worth up to $1 million each, support...